Neeraj K. Garg
Nikunj Tandel
Sanjay Kumar Bhadada
Rajeev K. Tyagi
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
- 2Institute of Science, Nirma University, Ahmedabad, India
- 3Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
- 4Division of Cell Biology and Immunology, Biomedical Parasitology and Nano-Immunology Lab, CSIR-Institute of Microbial Technology (IMTECH), Chandigarh, India
A Corrigendum on
Nanostructured lipid carrier–mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases
by Garg NK, Tandel N, Bhadada SK and Tyagi RK (2021). Front. Pharmacol. 12:713616. doi: 10.3389/fphar.2021.713616
In the original article, there was an error in Figure 2 as published. By mistake, an incorrect image for Figure 2A was supplied. The corrected Figure 2 appears below.
FIGURE 2
FIGURE 2. Microscopic analysis of shape and size of prepared formulations. (A) HR-TEM analysis and (B) SEM analysis of ACE-loaded CA-NLCs.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: aceclofenac, nanostructured lipid carrier, rheological behavior, texture profile, transdermal delivery
Citation: Garg NK, Tandel N, Bhadada SK and Tyagi RK (2022) Corrigendum: Nanostructured lipid carrier–mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases. Front. Pharmacol. 13:1002649. doi: 10.3389/fphar.2022.1002649
Received: 25 July 2022; Accepted: 29 July 2022;
Published: 25 August 2022.
Edited and reviewed by:
Letizia Polito, University of Bologna, ItalyCopyright © 2022 Garg, Tandel, Bhadada and Tyagi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rajeev K. Tyagi, cmFqZWV2dHlhZ2lAaW10ZWNoLnJlcy5pbg==, cmFqZWV2LmdydUBnbWFpbC5jb20=
†These authors have contributed equally to this work and share first authorship